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perspectives and evidence into Cochrane reviews
Ian Shemilt1, David McDaid2, Kevin Marsh3, Catherine Henderson2, Evelina Bertranou4, Jacqueline Mallander4,
Mike Drummond5, Miranda Mugford6, Luke Vale7* and On behalf of the Campbell and Cochrane Economics
Methods GroupAbstract
Background: Methods for systematic reviews of the effects of health interventions have focused mainly on
addressing the question of ‘What works?’ or ‘Is this intervention effective in achieving one or more specific
outcomes?’ Addressing the question ‘Is it worth it given the resources available?’ has received less attention. This
latter question can be addressed by applying an economic lens to the systematic review process.
This paper reflects on the value and desire for the consideration by end users for coverage of an economic
perspective in a Cochrane review and outlines two potential approaches and future directions.
Methods: Two frameworks to guide review authors who are seeking to include an economic perspective are
outlined. The first involves conducting a full systematic review of economic evaluations that is integrated into a
review of intervention effects. The second involves developing a brief economic commentary. The two approaches
share a set of common stages but allow the tailoring of the economic component of the Cochrane review to the
skills and resources available to the review team.
Results: The number of studies using the methods outlined in the paper is limited, and further examples are
needed both to explore the value of these approaches and to further develop them. The rate of progress will hinge
on the organisational leadership, capacity and resources available to the CCEMG, author teams and other Cochrane
entities. Particular methodological challenges to overcome relate to understanding the key economic trade-offs and
casual relationships for a given decision problem and informing the development of evaluations designed to
support local decision-makers.
Conclusions: Methods for incorporating economic perspectives and evidence into Cochrane intervention reviews
are established. Their role is not to provide a precise estimate of ‘cost-effectiveness’ but rather to help end-users of
Cochrane reviews to determine the implications of the economic components of reviews for their own specific
decisions.
Keywords: Cost-utility analysis, Cost-effectiveness analysis, Systematic review, Meta-analysis, Cochrane collaborationBackground
Methods for systematic reviews of health interventions
have focused mainly on addressing the question of
‘What works?’ or ‘Is this intervention effective in achie-
ving one or more specific outcomes?’ Systematic reviews
have addressed the efficiency of those interventions less
often. Yet such questions as ‘Is it worth it?’, ‘At what cost* Correspondence: luke.vale@newcastle.ac.uk
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reproduction in any medium, provided the oris the outcome achieved?’, and ‘What will be the eco-
nomic impact of this intervention?’ are crucial if health
systems are to use the resource they have available to
their best advantage. In times of financial austerity, these
questions take on particular importance. In his seminal
work Effectiveness and Efficiency: Random Reflections on
Health Services (authors’ emphasis), Archie Cochrane
stressed, as shown in the quotation below, the vital role
of economic evidence in health decision making [1]. As
The Cochrane Collaboration celebrates its 20th Anniver-
sary, we consider the extent to which the organisationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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need to take an efficiency perspective?
‘Allocation of funds and facilities are nearly always
based on the opinion of consultants but, more and more,
requests for additional facilities will have to be based on
detailed arguments with ‘hard evidence’ as to the gain to
be expected from the patient’s angle and the cost. Few
could possibly object to this’.
‘If we are ever going to get the ‘optimum’ results from
our national expenditure on the NHS we must finally be
able to express the results in the form of the benefit and
the cost to the population of a particular type of activity,
and the increased benefit that would be obtained if more
money were made available’ [1].
Decisions based on highly focused evidence-based
methodologies that consider only one dimension of rele-
vant evidence (that is, whether the intervention works)
may contribute to inefficient, or even wasteful, policy
and practice. Equally, a decision based on an economic
evaluation that does not utilise the most reliable evi-
dence for effectiveness will also be flawed, just as an un-
systematic review may lead to biased conclusions. A
better approach is to explicitly consider the trade-offs
between outcomes and cost. Studies of cost-effectiveness
may arrive at different conclusions than studies that
evaluate effectiveness and costs separately [2]; ideally,
consideration is needed of both effectiveness and cost
together to inform judgements on cost-effectiveness.
In this paper, we begin by briefly introducing economic
evaluation. We review the current prevalence and quality
of economic components of published Cochrane interven-
tion reviews and summarise approaches to incorporating
economic perspectives and evidence into such reviews.
We trace key methodological developments during theFigure 1 Decision-making relationship between effectiveness and cos
Cochrane Health Economics Group: especially Ron Akehurst, Martin Buxton
Jane Griffin, Sarah Howard, Tom Jefferson, Alastair McGuire, Bernie O’Brien,
inaugural meeting of the group in 1993.first 20 years of The Cochrane Collaboration and highlight
unresolved methodological issues that require further
research.
What is economic evaluation?
Economic evaluation involves the comparative analysis
of alternative actions in terms of their costs and effects
[3]. All types of economic evaluation seek to measure
the costs of providing interventions and their broader
cost consequences in the same way. The type of eco-
nomic evaluation will vary according to the unit of
measurement of benefit employed: for example, number
of symptom events observed (when combined with cost
data, this becomes a cost-effectiveness analysis); a mea-
sure of quality and quantity of life (cost-utility analysis),
or outcomes expressed in monetary terms (cost-benefit
analysis). Economic evaluation is used in many policy
areas, and governments and other agencies have pub-
lished methodological guidelines to help standardise
conduct [4-9].
Figure 1 shows that, relative to current practice, a new
health intervention could be (1) more effective, (2) of
equal effectiveness or (3) less effective. Of course, a
fourth option is possible whereby, after synthesising data
collected from all relevant studies, there is insufficient
evidence to conclude that the new intervention is more
or less effective. Economists bring considerations of
efficiency to the evaluation framework by adding the
measurement of resources to that of effectiveness. We
measure both the resources that are needed to provide
the interventions under investigation (the resource
inputs) and subsequent changes in the use of resources
that occur as a consequence of using an intervention
(resource consequences). For an economist the interestt*. *In this respect, we gratefully acknowledge other members of the
, Iain Chalmers, Ray Churnside, Paul Fenn, John Forbes, Alastair Gray,
Andy Oxman and Adrian Towse who formulated this figure at the
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these resources in natural units (for example, number of
days in hospital) to consideration of the value of re-
sources. Estimating the value of resources involves con-
sidering what benefits we could have obtained had we
not given up the opportunity to use the same resources
in another desirable way - this is the economic concept
of opportunity cost. Returning to Figure 1, in terms of
costs (that is, the monetised value of the resources
used), a new intervention could be (A) less costly, (B) of
equal cost, or (C) more costly, compared to current
practice. (Again, there is the possibility of there being
insufficient evidence to judge, as represented by row D).
For any intervention, the optimum position on the
matrix is square A1, where the new intervention would
both save costs and have greater effectiveness relative
to current practice (and so is a ‘recommended inter-
vention’). A2 and B1 are also more efficient than
current practice. B2 is neutral, with no difference in
cost or effectiveness. In squares marked with an ‘x’ the
new procedure is less efficient, while those marked
with a ‘?’ represent situations with insufficient evidence
on effectiveness and/or costs to make a judgement. Of
most interest are scenarios A3 and C1, where an im-
portant judgement must be made as to whether the
additional cost associated with the more costly inter-
vention is worth the additional effectiveness gained. To
aid such a judgement an incremental value of the bene-
fits gained can then be calculated along with an incre-
mental value of the cost incurred to achieve such a
gain.
Cochrane reviews and economic evidence
In recent years, evidence has accumulated that policy-
makers and other end-users would value more coverage
of economic perspectives in systematic reviews, pointing
to the sparseness of such evidence in Cochrane inter-
vention reviews and related products as a major gap
[3,10,11]. However, evidence on the quality and useful-
ness of economics components of published Cochrane
intervention reviews remains limited. In 2006 and 2007,
the Campbell and Cochrane Economics Methods Group
(CCEMG) conducted an audit of economic components
of all published Cochrane reviews [12]. This identified a
range of approaches to incorporating economic pers-
pectives and evidence that varied according to what
costs and benefits were deemed relevant, along with
inconsistencies between reviews in the application of
economics methods at each stage of the review process.
There were some examples of good practice, but also
many examples of injudicious application of methods
and interpretation of results. These findings informed
the development of new methods guidelines for Coch-
rane contributors on whether and how to incorporateeconomics methods into the Cochrane review process at
different levels [13]. As well as publication of methods
guidelines in the Cochrane Handbook, a suite of com-
panion training materials and tools for authors and
editors have been made available at methods training
workshops at annual Cochrane (and Campbell) colloquia
and online via the CCEMG website (www.c-cemg.org).
One key tension is that as economic evaluations are
conducted to inform specific decisions, some inputs to
economic evaluations, including estimates of resource
use and especially unit costs (that is, the opportunity
cost of single units of resource use), vary between set-
tings and over time [14]. Thus, the results of economic
evaluations can have limited generalisability and trans-
ferability between settings or over time. Conversely
(and while generalisability is also of equal concern for
effectiveness components of reviews), the findings of
Cochrane intervention reviews - including their eco-
nomic components - are intended to be useful to a glo-
bal audience of end users making specific decisions in
different contexts.
This has led some commentators to question the
value of incorporating economic perspectives and evi-
dence into Cochrane reviews. We have long argued
that such a conclusion is only valid if the economics
components of a Cochrane intervention review were
intended to produce definitive, widely applicable quan-
tified estimates of the differences in resource use, costs
and cost-effectiveness associated with the interven-
tions under investigation. However, we argue that the
starting point for economics components of Cochrane
intervention reviews needs to be different. This is why
Cochrane economics methods are not currently
oriented towards developing decision analytic model-
based economic evaluations as a further layer of
evidence synthesis within a Cochrane review (although
we argue that both economics and effectiveness com-
ponents of reviews should be useful to inform such
modelling exercises). Rather, the overall aim is to help
end-users understand key economic trade-offs between
alternative interventions, by summarising evidence for
resource use, costs and cost-effectiveness collected
from published economic evaluations conducted in dif-
ferent settings and at different times, and placing this
in the context of the best available evidence for inter-
vention effects [15,16]. Depending on the choice of
methods framework (see below), this summary will be
more or less detailed and may (in the case of a more
detailed summary) include a: critical appraisal of eli-
gible published economic evaluations; investigation of
factors likely to drive variations between settings and
over time; and (in both cases) a provisional assessment
of the extent to which an intervention is likely to be
judged favourably from an economic perspective.
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Frameworks for incorporating economic perspectives and
evidence
Two guiding frameworks for inclusion of economic per-
spectives in Cochrane reviews are currently offered. The
first involves a full systematic review of evidence from
previously published economic evaluations, integrated
into the systematic review of evidence from studies of
intervention effects. The second involves developing a
brief economic commentary to be incorporated into theFigure 2 Framework for incorporating economic perspectives into Cobackground and discussion sections of a Cochrane inter-
vention review. These two frameworks share some com-
mon stages of the review process, as set out in Figures 2
and 3.
The two frameworks differ in terms of time and ex-
pertise needed to complete the respective processes. A
full systematic review of economic evidence comprises
precisely the same stages as a systematic review of evi-
dence for effects and may add considerably to the work-
load of author teams producing the review (although inchrane intervention reviews: aims and assembly of data.
Figure 3 Framework for incorporating economic perspectives into Cochrane intervention reviews: presentation of economic data.
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be limited). Author teams considering use of this frame-
work are advised where possible to recruit an expe-
rienced health economist author or adviser, familiar with
Cochrane review methods, from the outset, to lead or
advise development of the economics component of the
review. Authors should contact their Cochrane Review
Group to check on the availability of a health economist
advisor and, if there is not a nominated health econo-
mist, contact the CCEMG (www.c-cemg.org). Economics
methods for conducting each stage of the systematic
review process are described in Chapter 15 of the
Cochrane Handbook [13] with a revised version being
prepared for publication in 2014 to reflect recent ad-
vances in the methods. Further supporting guidance and
tools for authors can be found on www.c-cemg.org.
A systematic review of economic evidence conducted
alongside a review of evidence of intervention effects is
recommended on three grounds. First, some of those
effects assessed as part of the effectiveness review will
also have impacts on resource use and associated costs.
For example, a new surgical intervention that reduces
rates of complications and revision procedures comparedwith current standard surgery will also lead to reductions
in the quantities of resources needed to manage complica-
tions and perform revision procedures. Second, a key part
of the assessment of risk of bias and methodological qua-
lity in published economic evaluations involves assessing
published effect sizes used within the economic evaluation
because such data are a subset of the data that might be
considered by a systematic review of effectiveness. Third,
a summary of evidence for impacts on resource use, costs
and cost-effectiveness is most useful to end users of re-
views when presented along with evidence for the direc-
tion and magnitude of intervention effects (as illustrated
by Figure 1). We anticipate that possible future deve-
lopments of Cochrane products may lead to this recom-
mendation being reviewed. For example, technological
developments may make it possible to link data to
Cochrane content; this could allow modular reviews to be
conducted separately and then linked to form bespoke
packages of evidence requested by end users of The
Cochrane Library. For instance, modules could be clus-
tered around a ‘standard model’ Cochrane intervention re-
view and configured to address linked sets of questions
about an intervention using different types of evidence.
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have evolved recently, as a means of promoting the en-
hancement of Cochrane intervention reviews with more
limited coverage of economic perspectives and evidence,
without placing major additional burden (in term of ex-
pertise and workload) on Cochrane author teams and
editorial bases. The process entails conducting sup-
plementary searches of the NHS Economic Evaluation
Database (NHS EED) and the Health Economic Evalua-
tions Database (HEED) to identify full-text reports of
relevant economic studies and their corresponding NHS
EED and HEED records, and using the information they
contain to develop brief, structured commentaries
(full details of the approach can be found on www.
c-cemg.org). Such an approach may also identify eco-
nomic modelling studies that might be overlooked if the
authors of such reviews limit their scope to economic
evaluations conducted within the framework of single
studies that meet eligibility criteria for the effectiveness
component of the review (for example, economic evalu-
ations conducted alongside included randomised con-
trolled trials). Full details of recommended methods,
including worked examples, and related training materials
are available on CCEMG website (www.c-cemg.org).
Incorporating economic perspectives and evidence
into Cochrane intervention reviews using either one of
the frameworks introduced in this section is currently
optional for Cochrane reviewers. It is therefore impor-
tant to highlight that authors can still configure their
Cochrane intervention reviews to help inform both the
production of new economic evaluations, and consi-
derations of economic issues by end users, even if they
decide against developing a formal economics compo-
nent using the frameworks described above. At the most
basic level, authors can record bibliographic details of
reports of population, intervention, comparator, out-
come (PICO)-relevant published economic evaluations
that they encounter when screening search results and
selecting studies of effects, and present these in an ap-
pendix to the published Cochrane review, possibly anno-
tated with links to corresponding NHS EED or HEED
structured abstract records (if available). This would
provide a useful resource for health economists and
other analysts working with health technology assess-
ment agencies, clinical guideline developers and other
organisations that are tasked with developing new eco-
nomic evaluations to inform specific decisions. Ad-
ditionally, some Cochrane intervention reviews could
benefit from consultation with a health economist
towards the end of the review process, to place an
‘economic lens’ on the reviewed evidence for effects.
This is because it is conceivable that, by considering the
balance of beneficial and adverse effects along with con-
sideration of the cost of providing an intervention andthe impact on use of services (often estimated as a
marker of effectiveness), a judgement may be possible as
to whether or not an intervention is likely to be consi-
dered favourably from an economic perspective. Al-
though great care must be taken not to over-interpret a
limited evidence base, placing an ‘economic lens’ on the
reviewed evidence for effects can allow tentative infe-
rences to be drawn. An example of this was a recent
study investigating the use of oesophageal Doppler
monitoring to assess cardiac output and haemodynamic
status, both considered key to improving outcome in
high risk surgery and critically ill patients. No economic
evaluations were available but the available data were
organised into a series of balance sheets outlining the
pros and cons of introducing this technology. Consi-
deration of this evidence suggested that the introduction
of oesophageal Doppler monitoring compared with con-
ventional monitoring was likely to improve outcomes
and that the upfront costs of providing oesophageal
Doppler monitoring would be very likely to be offset by
reductions in length of stay and the costs of managing
adverse effects [17] (and available free on line at http://
www.journalslibrary.nihr.ac.uk/hta/volume-13/issue-7).
In addition to considerations of resource use, costs
and cost-effectiveness, providing an economic pers-
pective can help end users of Cochrane reviews consider
the implications of adopting an intervention in different
settings. One way it can do this is by prompting the con-
sideration of what resources would be required to imple-
ment or scale up interventions; interventions with the
same apparent level of average cost-effectiveness can
have very different budgetary implications. A second
way is by prompting consideration of how costs and
cost-effectiveness might vary between different popu-
lation sub-groups. Consideration of how effectiveness
might vary between sub-groups is commonly addressed
in Cochrane intervention reviews, but the addition of an
economic lens might help focus on ‘economic’ reasons
why behaviour differs between sub-groups in addition to
biological or clinical reasons [18]. An example, of this
might be to consider how the uptake and efficiency of
public health interventions varies between socioeco-
nomic groups according to the type and magnitude of
financial incentives provided.
Cochrane reviews are only part of the evidence base re-
quired for decision-making. The Cochrane review process
provides an opportunity to assist in the decision-making
process in other ways. A positive spill-over (that is, a con-
sequence of a course of action that is in addition to the
one intended) from the Cochrane review process is the
opportunity that they provide to collate information to aid
development of new economic analyses. This may be par-
ticularly important in situations where there is a lack of
previous economic evaluations of interventions. An
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interventions. In this area high quality economic evalua-
tions are rare and further economic evaluation modelling
may be needed. The studies identified within a Cochrane
review may help inform the development of the disease
and care pathways that would form the basis of a subse-
quent economic evaluation model. The conceptualisation
of these pathways is a necessary precursor to the produc-
tion of a high quality model; it also provides a framework
which decision-makers can begin to create analyses ap-
plicable to their own jurisdiction. Ideally, other evidence
might be used to produce these conceptual models but fo-
cusing disease and care pathways from studies included in
the Cochrane intervention review also provides a mecha-
nism to consider the applicability of evidence on effective-
ness (and cost) from those studies for a specific context.
Likewise, Cochrane intervention reviews can also pro-
vide a mechanism for identifying evidence that might be
used in a subsequent modelling exercise to inform the
question ‘Is it worth it?’ These data might include evi-
dence of effectiveness, costs and the strength of pre-
ferences that patients and the public put on different
outcomes (‘utilities’ in economic parlance). It is likely
that sufficient data to inform an economic model will
not be available from the studies included in a Cochrane
review and that further dedicated research to identify
relevant robust information will be required. However,
the Cochrane intervention review provides an initial low
cost resource to identify such data.
Results and discussion
Cochrane economics methods: 1993 to 2013 and after 2013
As we reflect on the first 20 years of development of
economics methods for Cochrane reviews, it is apposite
to acknowledge the insight of those early leaders within
The Cochrane Collaboration who recognised a need for
the organisation to consider both efficiency and effec-
tiveness perspectives. We should also acknowledge the
legacy of those health economists who responded to this
challenge (named in the legend to Figure 1) by forming,
in 1993, the informal discussion group that evolved into
the Campbell and Cochrane Economics Methods Group.
However, the development and application of economics
methods in Cochrane reviews has progressed at a much
slower rate in comparison to the rapid growth in
production of Cochrane reviews more generally. Barriers
to this progress include: the specificity of economics
methods applicable for use in Cochrane intervention re-
views due to their global audience; limited availability of
resources and capacity to support Cochrane methods
development; and limited capacity and expertise to sup-
port the application of economics methods in reviews.
In this context, major challenges remain to building
capacity (through the training of Cochrane authors,editors and methodologists), to establishing a wider
economics methods network to support production of
economics components of Cochrane reviews, and to se-
curing funds to support further economics methods
development.
A number of notable milestones have been passed dur-
ing the first 20 years of the Cochrane Collaboration with
respect to economics. The NHS EED and HEED databases
have been established as key resources for the economics
components of reviews (both currently free at the point of
use to Cochrane contributors). The Methods Group was
co-registered with The Campbell Collaboration in 2003,
expanding its scope to cover the applied fields of crime
and justice, education, social welfare and (latterly) inter-
national development alongside health. Methods guide-
lines were first published in the Cochrane Handbook in
2008 [13]. A free online tool to automate the adjustment
of estimates of costs for currency and price year was
published in 2010 (http://eppi.ioe.ac.uk/costconversion/
default.aspx). A book describing state-of-the-art ap-
proaches to evidence synthesis that combine economics
and systematic review methods is now in its second edi-
tion [19,20]. The CCEMG has developed a new methods
framework for brief economic commentaries (www.
c-cemg.org). Most recently, methods guidelines have
been published on the use of the GRADE system to rate
quality of evidence for resource use and costs, which will
facilitate the incorporation of economic evidence into
Summary of Findings tables. These tables are increasingly
used in Cochrane to summarise principal findings and
quality of evidence for important outcomes [21].
Looking ahead to the next 20 years, the volume of
available economic evaluation will increase as economic
evaluations increasingly become required as part of trials
and other comparative studies by funding and regulatory
bodies. This growth of the evidence base indicates the
increasing need to consider economic evidence by
decision-makers. Methods for incorporating economic
perspectives and evidence into Cochrane intervention
reviews need to continue to evolve so that they better
meet decision-makers needs [22]. More Cochrane re-
views that utilise the methods frameworks we have
outlined here are therefore urgently needed. The rate of
progress will hinge on levels of organisational leadership,
commitment to and investment in the production of
economic components of Cochrane reviews, alongside
levels of capacity and resources in the CCEMG, author
teams, editorial bases and other Cochrane entities. In-
evitably, further, sustained economics methods research
and development are also needed. One major issue yet
to be addressed is the development of methods guide-
lines for incorporating economic perspectives and
evidence into Cochrane screening and diagnostic test ac-
curacy reviews.
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further development of economics methods for Cochrane
intervention reviews (and methods for systematic reviews
of economic evaluations more generally).
In recent work, Anderson and Shemilt discuss the pos-
sibility of producing pooled estimates of costs and cost-
effectiveness when conducting systematic reviews of
economic evaluations [15]. Arguing for a more explana-
tory approach to such reviews, they propose that the real
contribution of a systematic review of economic evidence
may not be to produce a single authoritative result, but to
help decision-makers understand the structure of the re-
source allocation problem addressed and the impact on
the overall result of key determinants of costs and cost-
effectiveness. The methods frameworks described above
in this paper are consistent with this view. Anderson and
Shemilt further argue that systematic reviews of economic
evaluations are likely to be most useful in: (i) identifying
the most relevant study (for the decision problem in hand)
for a particular setting; (ii) understanding the key eco-
nomic trade-offs and causal relationships in a decision
problem or policy area; or (iii) justifying and informing
decision model development.
A consideration of each of these three points in turn
demonstrates that further investigation is needed to clarify
how best to identify key studies with results that are appli-
cable or transferable to particular jurisdictions and key
economic trade-offs. With respect to key studies the value
of meta-analytic techniques to explore the impact of fac-
tors likely to explain variation (that is, investigate hete-
rogeneity) in estimates of resource use, costs and effects
between studies remains under-explored for economic
data. A multivariate meta-regression analysis, in principle,
allows the effects of multiple explanatory factors to be
investigated simultaneously. Brunetti and colleagues have
recently published brief guidance notes to inform judge-
ments about whether generating and presenting pooled
estimates of resource use and costs is likely to be appropri-
ate, with a view to investigating pre-specified factors that
may drive between-study heterogeneity in such estimates
[21]. They suggest that meta-analysis of estimates of spe-
cific items of resource use may be judged appropriate pro-
vided that the metric used to quantify such estimates is
common between studies (or a common metric can be
derived), and that meta-analysis of estimates of costs may
be judged appropriate in a more limited set of circum-
stances, and even then, only after estimates derived from
different studies have first been adjusted to a common cur-
rency and price year. However, we are not aware of any ex-
amples which have used standard meta-analytic techniques
to pool, and investigate ‘between-study’ heterogeneity in
published estimates of resources use and costs within a
systematic review framework. The feasibility and usefulness
of this approach therefore warrants further study.It is clear that many health technology assessment or-
ganisations, for example, NICE in England [7], now rely
on decision-analytic models to help assess the effective-
ness and cost-effectiveness of interventions. Cochrane
intervention reviews remain important inputs to this
process but are not sufficient. This is because individual
reviews do not include all relevant comparators, and
Cochrane reviews do not include the further level of evi-
dence synthesis that is provided by a decision-analytic
model. To ensure that Cochrane reviews remain relevant
to decision-making, the CCEMG needs to grapple with
this issue, which has at its heart consideration of the
transferability of findings. Some elements of a decision
model are more likely to be transferable than others. A
decision model describes two related processes - the
disease pathway and a prevention/care pathway. The
disease pathway is determined by underlying biology and
may be more transferable, whilst the prevention/care
pathway may be less transferable; but this does not pre-
clude the formulation of illustrative pathways that could
inform the development of context specific models in
particular settings. Such an approach might be further
enhanced should the concept of modular reviews be
adopted; illustrative models might be presented within a
module to assist in the development of models appli-
cable to particular end users. Furthermore, whilst cost
and utility data might have limited transferability (and
relevance to some decision makers [23]) the results of
an illustrative model might be specified in natural units
(for example, number of visits, length of stay) and
resulting health states (probabilities of death, survival
impaired, or with no problems).
Multi-level modelling is an alternative analytic tech-
nique that may hold some promise for investigation of
factors likely to explain variation in estimates of costs,
effects and cost-effectiveness within a systematic review
framework. Economic evaluations typically provide mul-
tiple estimates of resource use, costs and effects in the
form of both a ‘base case’ analysis and often extensive
sensitivity and sub-group analyses. Boehler [24], used
such techniques to explore the relative importance of
different predictive factors for the costs, effects and
cost-effectiveness of statins both within and between
studies and also between countries. The analytical ap-
proaches are complex and results may be biased if sen-
sitivity and sub-group analyses are selectively reported in
the index studies. Therefore, as with use of meta-regression
techniques, further exploration of multi-level modelling
approaches is needed.
Conclusions
Summary of key points for researchers
Methods for incorporating economic perspectives and
evidence into Cochrane intervention reviews are now
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review of health economic evaluations, fully integrated
with the parallel Cochrane review of intervention effects,
is not one to take lightly and this will require substantive
input from a health economist. The incorporation of a
brief economic commentary offers a simpler alternative
likely to be better suited to author teams with limited re-
sources and access to specialist expertise.
It is important to emphasise that the purpose of pro-
ducing economics components of Cochrane intervention
reviews is not to identify a single precise estimate of in-
cremental cost-effectiveness that is widely applicable to
the full range of decisions faced by end users. It is highly
unlikely that such an estimate could be transferable and,
though meta-analysis of cost data is technically possible,
the resultant pooled estimate is unlikely to be applicable
in any setting. Rather, the focus of narrative and statis-
tical approaches to the synthesis of economic evidence is
to identify key determinants of resource use, costs and/
or cost-effectiveness and to draw out how these determi-
nants may be distributed within and between settings.
With careful presentation and interpretation, this will
allow end users to determine the implications of findings
of economics components of reviews in their own
settings and to inform their particular context-specific
decisions.
Over 40 years ago Archie Cochrane recognised the
need to consider efficiency as well as effectiveness [1].
The methods to do this have been developed and should
be adopted more widely. Major challenges still exist and
the Cochrane Collaboration should aim to be at the
forefront of attempts to overcome them, in order to help
ensure that the work of the Cochrane Collaboration
remains of relevance to end users who have to make de-
cisions in the face of limited resources.
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